Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.84 USD
Change Today -0.33 / -4.60%
Volume 332.3K
BIND On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

bind therapeutics inc (BIND) Snapshot

Open
$7.25
Previous Close
$7.17
Day High
$7.33
Day Low
$6.80
52 Week High
07/2/14 - $13.72
52 Week Low
03/12/15 - $4.89
Market Cap
139.5M
Average Volume 10 Days
605.0K
EPS TTM
$-1.97
Shares Outstanding
20.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIND THERAPEUTICS INC (BIND)

Related News

No related news articles were found.

bind therapeutics inc (BIND) Related Businessweek News

No Related Businessweek News Found

bind therapeutics inc (BIND) Details

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specific pharmaceutical characteristics intended to target tumors at tissue, cellular, and molecular levels and to result in superior patient outcomes by enhancing the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. The company’s lead drug candidate includes BIND-014, a prostate-specific membrane antigen (PSMA) targeted Accurin that contains docetaxel, which is in Phase II clinical trials for non-small cell lung cancer. It is also developing BIND-510, a PSMA-targeted Accurin drug candidate containing the potent microtubule inhibitor vincristine. It has collaboration agreements to develop Accurins based on therapeutic payloads from their product pipelines with Amgen, Inc.; Pfizer Inc.; AstraZeneca AB; Hoffmann-La Roche Ltd.; and Merck & Co. The company was formerly known as BIND Biosciences, Inc. and changed its name to BIND Therapeutics, Inc. in April 2013. BIND Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

89 Employees
Last Reported Date: 03/11/15
Founded in 2006

bind therapeutics inc (BIND) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bind therapeutics inc (BIND) Key Developments

BIND Therapeutics Presents Data Highlighting Ability of Accurins to Control Biodistribution and Accumulate in Target Tissue at AACR Annual Meeting 2015

BIND Therapeutics, Inc. announced that clinical and preclinical data from its oncology pipeline, including proprietary and collaboration programs, were presented at the American Association of Cancer Research (AACR) Annual Meeting 2015. The presentations include data from the company’s lead proprietary Accurin drug candidate, BIND-014, and the Accurin drug candidate AZD2811, which is being developed in collaboration with AstraZeneca. The controlled biodistribution and potential for targeted and preferential tumor accumulation may result in increased efficacy and decreased toxicity with BIND-014. BIND-014 preclinical and clinical pharmacokinetics (PK) demonstrated monophasic plasma concentration-time profiles well differentiated from solvent-based docetaxel. The Accurin BIND-014 displayed higher peak plasma concentration [Cmax] and area under the curve [AUC] with reduced clearance [CL] and volume of distribution [V(d)] for total docetaxel compared to solvent-based docetaxel. In all species, the V(d) of BIND-014 was close to the blood volume. Cmax and AUC in human patients with solid tumors demonstrated dose linearity with an R2= 0.98; repeat dosing did not have a significant effect on Cmax. Evaluation of encapsulated docetaxel plasma concentrations in patients and cynomolgus monkeys demonstrated that most circulating docetaxel was encapsulated in nanoparticles. Time and duration of exposure is important and these data also indicate that the Accurin nanoparticle AZD2811 has the flexibility to be delivered with different doses/schedules, offering the potential to adapt the therapeutic regimen to different tumors while achieving an improved therapeutic index. Models of DLBCL and SCLC show sensitivity to monotherapy Aurora B kinase inhibitors and AZD2811, with increased time of exposure resulting in greater cell death. In vivo, Accurin nanoparticle AZD2811 inhibited tumor growth or resulted in tumor regression in multiple DLBCL and SCLC models. At 25mg/kg dosed on day 1 and 3, Accurin nanoparticle AZD2811 provided either equivalent or superior activity to AZD1152 delivered at 25mg/kg on days 1, 2, 3 and 4. Increased dose intensity resulted in increased anti-tumor effect, while modifying the timing and dose intensity of each dose cycle also influenced the anti-tumor activity.

BIND Therapeutics, Inc. Announces Extension of Global Collaboration with Pfizer Inc. to Develop and Commercialize Multiple Accurins

BIND Therapeutics, Inc. announced an extension of the terms of its global collaboration with Pfizer Inc. to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer's pipeline. The collaboration was originally established in April 2013 and the timeline for Pfizer to exercise its option to acquire the exclusive license for the first program continues to be September 2015. Both companies agreed to an extension of the timeline for the second program through March 2016.

BIND Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

BIND Therapeutics, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue of $3,037,000 against $2,070,000 a year ago. Loss from operations was $9,180,000 against $8,033,000 a year ago. Net loss attributable to common stockholders was $8,494,000 or $0.51 per basic and diluted share against $8,077,000 or $0.50 per basic and diluted share a year ago. The year-over-year increase in revenue was primarily due to higher reimbursable research and development activities, primarily for AstraZeneca collaboration. For the year, the company reported revenue of $10,426,000 against $10,901,000 a year ago. Loss from operations was $33,508,000 against $26,863,000 a year ago. Net loss attributable to common stockholders was $32,537,000 or $1.97 per basic and diluted share against $31,367,000 or $5.19 per basic and diluted share a year ago. The year-over-year decrease in revenue was primarily due to a reduction in up-front license fee revenue recognized that was partially offset by an increase in reimbursable research and development activities performed under collaboration agreements, principally for AstraZeneca, Pfizer and Roche.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIND:US $6.84 USD -0.33

BIND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIND.
View Industry Companies
 

Industry Analysis

BIND

Industry Average

Valuation BIND Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.4x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIND THERAPEUTICS INC, please visit bindtherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.